Tempest Therapeutics, Inc. (TPST) Stock Score, Valuation & Financial Research

Tempest Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TPST

Tempest Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.79. These figures are a research snapshot, not a buy or sell recommendation.

What Tempest Therapeutics, Inc. does

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tempest Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of oncology and immunology drug candidates.

Products and services

  • The company is developing a pipeline of small-molecule and cell therapy candidates, including amezalpat (a PPARα antagonist) and TPST-1495 (a dual EP2/EP4 antagonist), alongside various CAR-T cell therapy programs for cancer treatment.

Business relationships and partnerships

  • F. Hoffmann-La Roche Ltd — A clinical collaboration agreement to support the advancement of amezalpat in combination with atezolizumab and bevacizumab for the treatment of hepatocellular carcinoma. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting multiple oncology indications Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Need for additional capital to fund operations Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source · F. Hoffmann-La Roche Ltd

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TPST financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.79
Market capitalization:
12.58M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -40.47M
Free cash flow:
USD -26.82M
Cash:
USD 779K
Total debt:
USD 7.56M
EPS:
USD -4.48

What stands out

  • Free cash flow is USD -26.82M, negative for the stored period.
  • The balance sheet shows USD 779K of cash versus USD 7.56M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 6.78M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TPST

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TPST fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is TPST's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for TPST to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TPST's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TPST

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.